Cue Biopharma

Are you attending this year’s LSX USA Congress? Our CEO, Dan Passeri, will join fellow industry leaders on the panel presentation “Funding Biotech Innovation and Scaling Up” to discuss evolving operating models within biotech, delivering stakeholder value and more. For details: https://bit.ly/3XdisYC #LSXUSA

We are pleased to welcome industry veteran Lucinda Warren as chief business officer (CBO). Ms. Warren holds over 30 years of global industry experience and will play a pivotal role in advancing our core corporate objectives, following our recent business restructuring and autoimmune program prioritization. Learn more here: https://bit.ly/3MFWbxP

Members of management will deliver two presentations at this year’s The Promise of #Interleukin-2 Therapy Conference in Paris, France. Learn more here: https://bit.ly/3X9XgTo

We look forward to the 15th Annual World Bispecific Summit, where our Director of Translational Pharmacology, Natasha Girgis, will present on Immuno-STATs™: our novel class of T cell engagers for #AutoimmuneDisease. Learn more here: https://bit.ly/3AG5lHO

In case you missed it, we provided a business overview of our recent restructuring and near-term strategic prioritization objectives. Click here for the full webcast replay: https://bit.ly/4dUTnIH

Today, we announced our second quarter financial results and updated business highlights. Read our #PressRelease to learn more: https://bit.ly/3yVX41P

#SavetheDate for our upcoming #BusinessUpdate call on Monday, August 19 at 4:30 pm EDT. For more information and to access the live webcast link, click here: https://bit.ly/4fFzQ0B

In a Q&A with Drug Target Review our CSO Anish Suri, Ph. D., explores Cue Biopharma’s approach to translate nature’s cues into breakthrough #immunotherapies for autoimmune diseases and cancer. Read here: https://bit.ly/46Kt31L

In this pharmaphorum interview with Jonah Comstock, our CMO, Matteo Levisetti, M.D., discusses our recent #ASCO data and shares insights on our oncology programs, cancer immunotherapy and our differentiated Immuno-STAT™ platform potential. Access here: https://bit.ly/4bW994M

We are harnessing the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Check out our advancing pipeline of targeted interleukin 2 (IL-2) based #immunotherapies to learn more: https://bit.ly/3LrpFie